Cellmid Limited  

(Public, ASX:CDY)   Watch this stock  
Find more results for William N. Lucy
0.0380
+0.0020 (5.56%)
Jul 31 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.04 - 0.04
52 week 0.02 - 0.04
Open 0.04
Vol / Avg. 1.35M/4.12M
Mkt cap 28.63M
P/E     -
Div/yield     -
EPS 0.00
Shares 792.91M
Beta     -
Inst. own     -
Oct 9, 2015
Cellmid Ltd Annual Shareholders Meeting (Estimated) Add to calendar
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -145.96% -65.10%
Operating margin -292.52% -119.46%
EBITD margin - -114.53%
Return on average assets -30.47% -23.79%
Return on average equity -34.45% -26.80%
CDP Score - -

Address

City Freehold Se 1802 L 18, 15 Castlereagh St
SYDNEY, NSW 2000
Australia
+61-2-92216830 (Phone)
+61-2-92218535 (Fax)

Website links

Description

Cellmid Limited is an Australia-based biotechnology company. The Company operates in two segments: research and development of diagnostics and therapeutics and research, development and marketing of hair growth products. The Company is engaged in the development and commercialization of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (Midkine Business). The Company is also engaged in the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss and reestablish the natural hair growth cycle (OTC business). It is engaged in the development and sale of over the counter (OTC) treatments to alleviate excessive and abnormal hair loss and reestablish the natural hair growth cycle (Consumer Health Business).

Officers and directors

Maria Halasz Chief Executive Officer, Managing Director, Executive Director
Nicholas Falzon Financial Controller
Lucy N. Rowe Company Secretary
David William King Ph.D. Independent Non-Executive Chairman of the Board
Bruce Gordon Non-Executive Director
Edward Fintan Walton Non-Executive Director